Millions deprived of life saving antifungal medicines, report finds

August 11, 2016
Millions deprived of life saving antifungal medicines, report finds
Credit: University of Manchester

The world is in the grip of a global crisis that kills the equivalent of the populations of Philadelphia, Kampala or Prague - around 1.6 million each year.

A new report by a University of Manchester academic, published today in the Journal of Antimicrobial Chemotherapy, documents how many countries do not have life-saving antifungal therapies.

Fungal infections attack the lungs and may spread through the body and, without the drugs to fight back, claim the lives of over 3,500 people every day.

Now GAFFI (The Global Action Fund for Fungal Infections) has gathered together the most powerful weapon there is – knowledge – information that it plans to use to bring about change.

It has today published the largest survey ever undertaken from 159 countries and found that two critical antifungal medicines for AIDS patients are not available in over 95 countries. One of these antifungals has been available since the 1950s and the other since the 1970s.

Professor David Denning of The University of Manchester, President of GAFFI and the paper's lead author says it beggars belief that hundreds of millions of people cannot access the optimal therapy for fungal meningitis and fungal lung infections.

The video will load shortly
Credit: University of Manchester

"It is doubly tragic," he said, "That these antifungals have been used since the late 1950s in the case of amphotericin B. Yet the systems for delivering these drugs to the most needy are still not in place.

"Last year GAFFI called on governments to provide fungal diagnostics and to all their citizens yet there has been a deafening silence. There is clearly a long way to go, but the tragedy is that every day thousands more people die needlessly while the world turns a blind eye," he added.

Actor and GAFFI celebrity patron Rupert Everett declared that: "We have known for over 25 years that many people with AIDS and cancer do die of fungal complications. And death is avoidable with treatment. Why on earth are commonly used antifungal medicines not provided to everyone who needs them?"

Dr Glenda Gray, President and CEO of the African Medical Research Council and Professor of Pediatrics, Faculty of Health Sciences, at University of Witwatersrand, said: "In South Africa we are addressing the HIV epidemic squarely on with greatly increased provision of anti-retroviral drugs and expanding testing.

"Fungal diseases in AIDS have not received the priority they should have, although this is now changing with our national screening program for Cryptococci meningitis. Clearly ensuring antifungal agents are available to all is an key component in reducing deaths and illness across southern Africa."

Key findings:

  • One of the critical drugs for fungal meningitis in AIDS (amphotericin B) is not available in 42 countries. The other key drug for , flucytosine, is unavailable in at least 95 countries. Yet both have been available in Europe and the US for over 40 years. The World Health Organization recommends they be used together to bring down mortality from 100% to 25%. Fungal meningitis is the commonest form of meningitis in sub-Saharan Africa because of AIDS.
  • The 25 -year old drug, fluconazole is available in all countries and itraconazole is unavailable in just five countries. However, being available is not enough – price also matters as patients pay for their care in many countries. The daily cost of fluconazole varied from <$1 to $31 and itraconazole from <$1 to $102. In South Africa, which has the largest AIDS burden in the world and a massive TB problem, itraconazole costs about £11.60 per day – unaffordable for most people there.

Explore further: No response to first antifungals tied to worse keratitis outcomes

More information: Global access to antifungal therapy and its variable cost. J. Antimicrob. Chemother. first published online August 10, 2016 DOI: 10.1093/jac/dkw325

Related Stories

Breast cancer drug fights fungal disease

February 11, 2014

Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more ...

Recommended for you

Most dengue infections transmitted in and around home

March 23, 2017

Transmission of the mosquito-borne dengue virus appears to be largely driven by infections centered in and around the home, with the majority of cases related to one another occurring in people who live less than 200 meters ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

jhnycmltly
not rated yet Aug 14, 2016
In the meantime a tablespooon of oil might be of use.

"essential fatty acids also have antibacterial, antifungal and antiviral action."
" linolenic acid rapidly killed cultures of Staphylococcus aureus applied to the skin and suggested a therapeutic role for naturally occurring free fatty acids."
"It would be interesting to use these essential fatty acids with or without antibiotics in bacterial, viral and fungal infections. In conditions such as herpes simplex and herpes zoster and, perhaps, in localized bacterial and fungal infections, essential fatty acids, could be applied locally or given subcutaneously. Evening primrose oil, fish oil and linseed oil, which are rich in linoleic, linolenic and eicosapentanoic acid, may be used. These oils are nontoxic and are easily absorbed from the skin and mucous membranes."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.